BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 23207522)

  • 1. Contributions of the RhoGEF activity of p210 BCR/ABL to disease progression.
    Tala I; Chen R; Hu T; Fitzpatrick ER; Williams DA; Whitehead IP
    Leukemia; 2013 Apr; 27(5):1080-9. PubMed ID: 23207522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity.
    Li S; Ilaria RL; Million RP; Daley GQ; Van Etten RA
    J Exp Med; 1999 May; 189(9):1399-412. PubMed ID: 10224280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The RhoGEF domain of p210 Bcr-Abl activates RhoA and is required for transformation.
    Sahay S; Pannucci NL; Mahon GM; Rodriguez PL; Megjugorac NJ; Kostenko EV; Ozer HL; Whitehead IP
    Oncogene; 2008 Mar; 27(14):2064-71. PubMed ID: 17922031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Examination of clinically-derived p210 BCR/ABL1 RhoGEF mutations in a murine bone marrow transplantation model of CML.
    Ciccarelli BT; Hu T; Wang Q; Kim JJ; Whitehead IP
    Leuk Res; 2020 Oct; 97():106440. PubMed ID: 32892149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia.
    Zhang X; Ren R
    Blood; 1998 Nov; 92(10):3829-40. PubMed ID: 9808576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ubiquitin-mediated interaction of p210 BCR/ABL with β-catenin supports disease progression in a murine model for chronic myelogenous leukemia.
    Chen R; Hu T; Mahon GM; Tala I; Pannucci NL; Ozer HL; Whitehead IP
    Blood; 2013 Sep; 122(12):2114-24. PubMed ID: 23950177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular analysis of lineage-specific chimerism and minimal residual disease by RT-PCR of p210(BCR-ABL) and p190(BCR-ABL) after allogeneic bone marrow transplantation for chronic myeloid leukemia: increasing mixed myeloid chimerism and p190(BCR-ABL) detection precede cytogenetic relapse.
    Serrano J; Roman J; Sanchez J; Jimenez A; Castillejo JA; Herrera C; Gonzalez MG; Reina L; Rodriguez MC; Alvarez MA; Maldonado J; Torres A
    Blood; 2000 Apr; 95(8):2659-65. PubMed ID: 10753848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase.
    Roumiantsev S; de Aos IE; Varticovski L; Ilaria RL; Van Etten RA
    Blood; 2001 Jan; 97(1):4-13. PubMed ID: 11133737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential motility of p190bcr-abl- and p210bcr-abl-expressing cells: respective roles of Vav and Bcr-Abl GEFs.
    Daubon T; Chasseriau J; El Ali A; Rivet J; Kitzis A; Constantin B; Bourmeyster N
    Oncogene; 2008 Apr; 27(19):2673-85. PubMed ID: 18059343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Invadopodia and rolling-type motility are specific features of highly invasive p190(bcr-abl) leukemic cells.
    Daubon T; Rochelle T; Bourmeyster N; Génot E
    Eur J Cell Biol; 2012; 91(11-12):978-87. PubMed ID: 22717125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells.
    Gross AW; Ren R
    Oncogene; 2000 Dec; 19(54):6286-96. PubMed ID: 11175343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential interaction and activation of Rho family GTPases by p210bcr-abl and p190bcr-abl.
    Harnois T; Constantin B; Rioux A; Grenioux E; Kitzis A; Bourmeyster N
    Oncogene; 2003 Sep; 22(41):6445-54. PubMed ID: 14508524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias.
    van Rhee F; Hochhaus A; Lin F; Melo JV; Goldman JM; Cross NC
    Blood; 1996 Jun; 87(12):5213-7. PubMed ID: 8652835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential signaling networks of Bcr-Abl p210 and p190 kinases in leukemia cells defined by functional proteomics.
    Reckel S; Hamelin R; Georgeon S; Armand F; Jolliet Q; Chiappe D; Moniatte M; Hantschel O
    Leukemia; 2017 Jul; 31(7):1502-1512. PubMed ID: 28111465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BCR/ABL P210 and P190 cause distinct leukemia in transgenic mice.
    Voncken JW; Kaartinen V; Pattengale PK; Germeraad WT; Groffen J; Heisterkamp N
    Blood; 1995 Dec; 86(12):4603-11. PubMed ID: 8541551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of P190 and P210 BCR/ABL1 in normal human CD34(+) cells induces similar gene expression profiles and results in a STAT5-dependent expansion of the erythroid lineage.
    Järås M; Johnels P; Agerstam H; Lassen C; Rissler M; Edén P; Cammenga J; Olofsson T; Bjerrum OW; Richter J; Fan X; Fioretos T
    Exp Hematol; 2009 Mar; 37(3):367-75. PubMed ID: 19135771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line.
    Matulonis U; Salgia R; Okuda K; Druker B; Griffin JD
    Exp Hematol; 1993 Oct; 21(11):1460-6. PubMed ID: 8405226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Sequential analysis of p210- and p190-bcr-abl by RT-PCR after allogeneic bone marrow transplantation for p210/p190-bcr-abl double positive acute lymphoblastic leukemia].
    Fujimaki K; Maruta A; Yoshida M; Yamazaki E; Motomura S; Kodama F; Matsuzaki M; Fujisawa S; Kanamori H; Ishigatsubo Y
    Rinsho Ketsueki; 2001 Feb; 42(2):89-93. PubMed ID: 11280922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BCR/ABL p210, p190 and p230 fusion genes in 250 Mexican patients with chronic myeloid leukaemia (CML).
    Arana-Trejo RM; Ruíz Sánchez E; Ignacio-Ibarra G; Báez de la Fuente E; Garces O; Gómez Morales E; Castro Granados M; Ovilla Martínez R; Rubio-Borja ME; Solís Anaya L; Herrera P; Delgado Llamas J; Kofman S
    Clin Lab Haematol; 2002 Jun; 24(3):145-50. PubMed ID: 12067277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin 3 and granulocyte-macrophage colony-stimulating factor are not required for induction of chronic myeloid leukemia-like myeloproliferative disease in mice by BCR/ABL.
    Li S; Gillessen S; Tomasson MH; Dranoff G; Gilliland DG; Van Etten RA
    Blood; 2001 Mar; 97(5):1442-50. PubMed ID: 11222392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.